ALPMF Quote, Financials, Valuation and Earnings

Nxera Pharma Co., Ltd. has a net margin of 15.11% compared to Astellas Pharma, Inc.'s net margin of -24.76%. Astellas Pharma, Inc.'s return on equity of 8.36% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.

Astellas Pharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma, Inc. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Astellas Pharma, Inc. is more attractive than Nxera Pharma Co., Ltd..

Astellas Pharma, Inc. has a beta of 0.069, which suggesting that the stock is 93.111% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.

Astellas Pharma, Inc. has a quarterly dividend of $0.26 per share corresponding to a yield of 3.59%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma, Inc. pays 261.11% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.

Astellas Pharma, Inc. quarterly revenues are $3.6B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Astellas Pharma, Inc.'s net income of $537.1M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Astellas Pharma, Inc.'s price-to-earnings ratio is 29.68x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma, Inc. is 1.89x versus 2.56x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Stemcell Holdings, Inc. has a net margin of 15.11% compared to Astellas Pharma, Inc.'s net margin of --. Astellas Pharma, Inc.'s return on equity of 8.36% beat Stemcell Holdings, Inc.'s return on equity of --.

Astellas Pharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma, Inc. has higher upside potential than Stemcell Holdings, Inc., analysts believe Astellas Pharma, Inc. is more attractive than Stemcell Holdings, Inc..

Astellas Pharma, Inc. has a beta of 0.069, which suggesting that the stock is 93.111% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astellas Pharma, Inc. has a quarterly dividend of $0.26 per share corresponding to a yield of 3.59%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma, Inc. pays 261.11% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.

Astellas Pharma, Inc. quarterly revenues are $3.6B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Astellas Pharma, Inc.'s net income of $537.1M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Astellas Pharma, Inc.'s price-to-earnings ratio is 29.68x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma, Inc. is 1.89x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical Co., Ltd. has a net margin of 15.11% compared to Astellas Pharma, Inc.'s net margin of -1.05%. Astellas Pharma, Inc.'s return on equity of 8.36% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.

Astellas Pharma, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 13.63%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Astellas Pharma, Inc., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Astellas Pharma, Inc..

Astellas Pharma, Inc. has a beta of 0.069, which suggesting that the stock is 93.111% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.

Astellas Pharma, Inc. has a quarterly dividend of $0.26 per share corresponding to a yield of 3.59%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.2% to investors and pays a quarterly dividend of $0.32 per share. Astellas Pharma, Inc. pays 261.11% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Astellas Pharma, Inc. quarterly revenues are $3.6B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Astellas Pharma, Inc.'s net income of $537.1M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Astellas Pharma, Inc.'s price-to-earnings ratio is 29.68x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 200.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma, Inc. is 1.89x versus 1.70x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.